Practical Neurology Podcast Guidelines on disease-modifying treatment in MS: a decade-long update
Mar 26, 2025
Tamara Kaplan, an MS specialist at Harvard Medical School, and Michael Barnett, a consultant neurologist from Sydney, dive deep into the latest guidelines on disease-modifying treatments for multiple sclerosis. They discuss the evolution and importance of these therapies, emphasizing early intervention. The duo also navigates the complexities of individualized treatment approaches, including safety during pregnancy and the challenges posed by varying healthcare systems. Case studies illustrate the necessity for personalized care in MS management, highlighting a global perspective on the issue.
AI Snips
Chapters
Transcript
Episode notes
Early High-Efficacy Therapy
- Consider high-efficacy therapies for MS early.
- Discuss these therapies in a multidisciplinary setting.
MS as a Continuum
- MS should be viewed as a continuum, not separate diseases.
- This approach impacts treatment decisions.
High-Efficacy Therapy First
- Prioritize high-efficacy MS therapy as a first option for eligible patients.
- This approach challenges the traditional escalation approach.